Sugammadex Piramal Unione Europea - italiano - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - blocco neuromuscolare - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Sugammadex Mylan Unione Europea - italiano - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi Unione Europea - italiano - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed Unione Europea - italiano - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - inversione del blocco neuromuscolare indotto da rocuronio o vecuronio. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Adroiq Unione Europea - italiano - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.